Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL

BACKGROUND: This study was performed to examine the usefulness of combined androgen blockade (CAB) therapy with a gonadotropin-releasing hormone (GnRH) antagonist (CAB-antagonist therapy), instead of CAB therapy with GnRH agonist (CAB-agonist therapy) against very high-risk prostate cancer (Pca). ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashiwabara, Takeshi, Suda, Sayo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984333/
https://www.ncbi.nlm.nih.gov/pubmed/29855278
http://dx.doi.org/10.1186/s12885-018-4541-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984333/
https://www.ncbi.nlm.nih.gov/pubmed/29855278
http://dx.doi.org/10.1186/s12885-018-4541-0

Ejemplares similares